欧盟EMA药品数据库-欧盟集中审批药品（European Medicines Agency Authorisation of Medicines DataBase）

商品名称	适用类别	通用名称	活性成分	产品号	上市许可开发者/申请人/持有人	上市许可日期	许可状态
Beyonttra	Human	acoramidis	acoramidis hydrochloride	EMEA/H/C/006333	Bayer AG	2025/02/10	Authorised
Korjuny	Human	catumaxomab	catumaxomab	EMEA/H/C/005697	Atnahs Pharma Netherlands B.V.	2025/02/10	Authorised
Andembry	Human	garadacimab	garadacimab	EMEA/H/C/006116	CSL Behring GmbH	2025/02/10	Authorised
Hetronifly	Human	serplulimab	serplulimab	EMEA/H/C/006170	Accord Healthcare S.L.U.	2025/02/03	Authorised
Lazcluze	Human	lazertinib	lazertinib mesilate monohydrate	EMEA/H/C/006074	Janssen Cilag International NV	2025/01/20	Authorised
Kavigale	Human	sipavibart	sipavibart	EMEA/H/C/006291	AstraZeneca AB	2025/01/20	Authorised
Gohibic	Human	vilobelimab	vilobelimab	EMEA/H/C/006123	InflaRx GmbH	2025/01/13	Authorised
Baiama	Human	aflibercept	aflibercept	EMEA/H/C/005980	Formycon AG	2025/01/13	Authorised
Ahzantive	Human	aflibercept	aflibercept	EMEA/H/C/006607	Formycon AG	2025/01/13	Authorised
Siiltibcy	Human	Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10)	Mycobacterium tuberculosis derived antigens (rdESAT‑6 and rCFP‑10)	EMEA/H/C/006177	Serum Life Science Europe GmbH	2025/01/13	Authorised
Augtyro	Human	repotrectinib	repotrectinib	EMEA/H/C/006005	Bristol-Myers Squibb Pharma EEIG	2025/01/13	Authorised
Buprenorphine Neuraxpharm	Human	buprenorphine	buprenorphine hydrochloride	EMEA/H/C/006188	Neuraxpharm Pharmaceuticals S.L.	2024/12/19	Authorised
Alhemo	Human	concizumab	concizumab	EMEA/H/C/005938	Novo Nordisk A/S	2024/12/13	Authorised
Eltrombopag Viatris	Human	eltrombopag	eltrombopag olamine	EMEA/H/C/006417	Viatris Limited	2024/12/12	Authorised
Imuldosa	Human	ustekinumab	ustekinumab	EMEA/H/C/006221	Accord Healthcare S.L.U.	2024/12/12	Authorised
Absimky	Human	ustekinumab	ustekinumab	EMEA/H/C/006585	Accord Healthcare S.L.U.	2024/12/12	Withdrawn
Theralugand	Human	lutetium (177Lu) chloride	lutetium (177Lu) chloride	EMEA/H/C/005882	Eckert & Ziegler Radiopharma GmbH	2024/11/22	Authorised
Hympavzi	Human	marstacimab	marstacimab	EMEA/H/C/006240	Pfizer Europe MA EEIG	2024/11/18	Authorised
Flucelvax	Human	influenza vaccine (surface antigen, inactivated, prepared in cell cultures)	A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) / A/District of Columbia/27/2023 (H3N2)-like strain (A/Victoria/800/2024 CVR-289) / B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021)	EMEA/H/C/006532	Seqirus Netherlands B.V.	2024/11/15	Authorised
Fluad	Human	influenza vaccine (surface antigen, inactivated, adjuvanted)	A/Victoria/4897/2022 (H1N1)pdm09 like strain (A/Victoria/4897/2022, IVR-238);A/Croatia/10136RV/2023 (H3N2)-like strain (A/Croatia/10136RV/2023, X-425A);B/Austria/1359417/2021 like strain (B/Austria/1359417/2021, BVR-26)	EMEA/H/C/006538	Seqirus Netherlands B.V.	2024/11/15	Authorised

商品名称Name of medicine	*示例：Zokinvy（英文）
药品通用名或非专利名称International non-proprietary name (INN) / common name	*示例：lonafarnib（英文）
活性成分Active substance	*示例：lonafarnib（英文）
产品号EMA product number	*示例：EMEA/H/C/005271
ATC编号ATC code	*示例：L01EA06
上市许可开发者/申请人/持有人Marketing authorisation developer / applicant / holder	*示例：Janssen
药物治疗学分组Pharmacotherapeutic group	*示例：Antineoplastic
适应症Therapeutic indication	*示例：leukaemia
许可状态Medicine status
上市许可日期Marketing authorisation date	-